The Roivant Paradox: Shareholder Absurdity and the Analyst’s Edict

David Risinger, the Leerink Partners scribe, had etched his verdict in the pre-market hours: a $18 price target, a “buy” recommendation, and the bureaucratic alchemy of share count forecasts. His analysis, a tautology wrapped in jargon, cited management’s promises of share repurchases-a promise as tangible as a mirage in a desert of quarterly reports. The analyst, a figure both omnipotent and invisible, framed this as a triumph of logic over chaos, though no one could say why a dollar more justified such faith.







